New Drug Approvals Archive

New Drug Approvals: June 2008

June 5
Reclast (zoledronic acid)

New Indication Approved: June 3, 2008

FDA broadens US indication for once-yearly Reclast as only osteoporosis treatment approved for prevention of fractures after a hip fracture
 
June 16
Requip (ropinirole)

New Dosage Form Approved: July 1, 2008

U.S. FDA Approves Requip XL, the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
 
June 16
Cymbalta (duloxetine)

New Indication Approved: June 13, 2008

FDA Approves Cymbalta for the Management of Fibromyalgia
 
June 16
Trivaris (triamcinolone acetonide) Intravitreal Injection

Date of Approval: June 16, 2008

Company: Allergan, Inc.

Treatment for: Ocular Inflammatory Conditions

Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Allergan Receives U.S. Food and Drug Administration Approval for Trivaris (triamcinolone acetonide injectable suspension) 80 mg/mL
 
June 20
Avodart (dutasteride)

New Indication Approved: June 19, 2008

FDA Approves GlaxoSmithKline's Avodart in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
 
June 20
Pentacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine)

Date of Approval: June 20, 2008

Company: Sanofi pasteur

Treatment for: Pertussis Prophylaxis, Tetanus Prophylaxis, Diphtheria Prophylaxis, Poliomyelitis Prophylaxis, Haemophilus influenzae Prophylaxis

Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel
 
June 23
Velcade (bortezomib)

New Indication Approved: June 20, 2008

FDA Approves Velcade (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
 
June 23
PrandiMet (repaglinide and metformin) Tablets

Date of Approval: June 23, 2008

Company: Sciele Pharma, Inc. and Novo Nordisk Inc.

Treatment for: Diabetes Mellitus Type II

PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

FDA Approves PrandiMet, a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes
 
June 23
Durezol (difluprednate) Ophthalmic Emulsion

Date of Approval: June 23, 2008

Company: Sirion Therapeutics, Inc.

Treatment for: Postoperative Ocular Inflammation

Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain
 
June 24
Aptivus (tipranavir)

New Dosage Form Approved: June 23, 2008

New Aptivus (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
 
June 24
Kinrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine)

Date of Approval: June 24, 2008

Company: GlaxoSmithKline

Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Poliomyelitis Prophylaxis, Pertussis Prophylaxis

Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

FDA Approves Kinrix - New Combination Vaccine for Children
 
June 27
Concerta (methylphenidate)

Patient Population Altered: June 27, 2008

FDA Approves Concerta (methylphenidate HCl) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
 
June 27
Metvixia (methyl aminolevulinate hydrochloride)

New Formulation Approved: June 26, 2008

Photocure Receives FDA Approval for Metvixia/Aktilite Photodynamic Therapy
 
June 27
Evolence (dermal filler)

Date of Approval: June 27, 2008

Company: OrthoNeutrogena

Treatment for: Facial Wrinkles

Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

FDA Approves Evolence, a New Generation Collagen-Based Facial Filler
 
June 10
Evolence (dermal filler)

Labeling Revision Approved: June 8, 2009

Treatment for: Facial Wrinkles

FDA Approves 12-Month Labeling Update for Evolence Collagen-Based Facial Filler
 

New Drug Approvals Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Feb | Jul | Aug | Oct | Nov | Dec

MedNotes
Advertisement

(web1)